HMB Hydroxymethylbutyrate.

Leucine is transaminated to alpha-ketoisocaproate, and a small fraction of that KIC is oxidised by KIC dioxygenase to HMB. Supplementing HMB directly bypasses this conversion bottleneck, which is why HMB doses are far smaller than the leucine intake that would generate them. The two are not interchangeable: leucine also signals mTORC1 directly, which HMB does only weakly. Taking both covers the direct signalling and the metabolite arm.

A signalling stimulus without substrate produces nothing. HMB influences the balance between muscle protein synthesis and breakdown, but the building blocks have to arrive from dietary protein. In studies where total protein intake was already adequate, added HMB has generally shown smaller effects than in studies with low baseline intake or in catabolic states. The pairing matters most when protein intake is marginal.

Most clinical work on HMB in older adults used a multi-ingredient oral nutrition supplement in which vitamin D was a co-ingredient, so the two are hard to separate in the existing data. Vitamin D acts through the nuclear vitamin D receptor in muscle, a different route from HMB. Where baseline vitamin D status is low, correcting it plausibly permits a better response to any anabolic input. This is inference from trial design and separate mechanisms, not a tested interaction.

Creatine increases the amount of high-intensity work that can be performed in a session, which raises the training stimulus itself. HMB acts downstream on the synthesis and breakdown balance in the recovery window. Because the entry points differ, the effects are not expected to overlap. Head-to-head data on the combination is thinner than on either alone, and some combination trials have not separated the two contributions.

HMB acts on skeletal muscle protein turnover while collagen preparations act on connective tissue and, in the undenatured type-II form, through an oral tolerance route. The rationale for combining them is that muscle strength and joint comfort during activity are linked in older adults. The combination has been formally studied, so the design exists, but the two ingredients' separate contributions are not resolved.

Branched-chain aminotransferase is a PLP-dependent enzyme, so vitamin B6 status governs the rate at which dietary leucine can be converted toward KIC and onward to HMB. This applies to endogenous HMB production, not to supplemental HMB, which enters already formed. The relevance is to anyone relying on dietary leucine rather than a direct HMB dose.

Beta-alanine raises muscle carnosine, which buffers intracellular pH during high-intensity work. HMB affects protein turnover balance and does not influence buffering capacity. Stacking them targets two independent limiting factors. Direct combination data in humans is limited, so this rests on non-overlapping mechanisms rather than a tested pairing.